(RTTNews) - Friday, Eli Lilly (LLY) reported new exploratory Phase 3b data from the TOGETHER-PsO study evaluating Taltz (ixekizumab) and Zepbound (tirzepatide) in adults with psoriasis and obesity or overweight.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.